The Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts report provides
comprehensive understanding and unprecedented access to the stem cell
partnering deals and agreements entered into by the worlds leading healthcare
companies.
- Trends in stem cell partnering
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for stem cells
The report provides a detailed
understanding and analysis of how and why companies enter Stem Cell partnering
deals. These deals tend to be multicomponent, starting with collaborative
R&D, and proceed to commercialization of outcomes.
This report provides details of
the latest Stem Cell agreements announced in the life sciences since 2010.
The report takes the reader
through a comprehensive review Stem Cell deal trends, key players, top deal
values, as well as deal financials, allowing the understanding of how, why and
under what terms, companies are entering Stem Cell partnering deals.
The report presents financial deal
term values for Stem Cell deals, listing by headline value, upfront payments,
milestone payments and royalties, enabling readers to analyse and benchmark the
financial value of deals.
The middle section of the report
explores the leading dealmakers in the Stem Cell partnering field; both the
leading deal values and most active Stem Cell dealmaker companies are reported
allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the
report is that over 500 online deal records of actual Stem Cell deals, as
disclosed by the deal parties, are included towards the end of the report in a
directory format – by company A-Z, stage of development, deal type, therapy
focus, and technology type - that is easy to reference. Each deal record in the
report links via Weblink to an online version of the deal.
In addition, where available,
records include contract documents as submitted to the Securities Exchange
Commission by companies and their partners. Whilst many companies will be
seeking details of the payment clauses, the devil is in the detail in terms of
how payments are triggered – contract documents provide this insight where
press releases and databases do not.
The initial chapters of this
report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an overview of the trends
in Stem Cell dealmaking since 2010, including details of headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the
leading Stem Cell deals since 2010. Deals are listed by headline value. Where
the deal has an agreement contract published at the SEC a link provides online
access to the contract.
Chapter 4 provides a comprehensive
listing of the top 25 most active companies in Stem Cell dealmaking with a
brief summary followed by a comprehensive listing of Stem Cell deals announded
by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive
and detailed review of Stem Cell partnering deals signed and announced since
Jan 2010, where a contract document is available in the public domain. Each
deal title links via Weblink to an online version of the deal record and
contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive
and detailed review of Stem Cell partnering deals signed and announced since
Jan 2010. The chapter is organized by specific Stem Cell technology type. Each
deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each deal on demand.
A comprehensive series of
appendices is provided organized by Stem Cell partnering company A-Z, stage of
development, deal type, and therapy focus. Each deal title links via Weblink to
an online version of the deal record and where available, the contract
document, providing easy access to each deal on demand.
The report also includes numerous
tables and figures that illustrate the trends and activities in Stem Cell
partnering and dealmaking since 2010.
In conclusion, this report
provides everything a prospective dealmaker needs to know about partnering in
the research, development and commercialization of Stem Cell technologies and
products.
Key benefits
Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts provides the reader
with the following key benefits:
- In-depth understanding of Stem Cell deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Stem Cell agreements with numerous real life case studies
- Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
- Identify most active Stem Cell dealmakers since 2010
- Insight into terms included in a Stem Cell partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts is intended to
provide the reader with an in-depth understanding and access to Stem Cell
trends and structure of deals entered into by leading companies worldwide.
Stem Cell Partnering Terms and
Agreements includes:
- Trends in Stem Cell dealmaking in the biopharma industry since 2010
- Analysis of Stem Cell deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Stem Cell deals
- Access to Stem Cell contract documents
- Leading Stem Cell deals by value since 2010
- Most active Stem Cell dealmakers since 2010
In Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts, the available deals
are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink
to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts report provides
comprehensive access to available deals and contract documents for over 500
Stem Cell deals.
Analyzing actual contract
agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Stem Cell Partnering
2010-2016: Deal trends, players, financials and forecasts provides the reader
with the following key benefits:
- In-depth understanding of stem cell deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of stem cell agreements with numerous real life case studies
- Detailed access to actual stem cell contracts entered into by leading biopharma companies
- Identify most active stem cell dealmakers since 2010
- Insight into terms included in a stem cell partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 370 pages “Global Stem Cell Partnering 2010-2016: Deal trends,
players, financials and forecasts” report
covers Introduction, Trends in Stem Cell dealmaking, Leading Stem Cell deals,
Most active Stem Cell dealmakers, Stem Cell contracts dealmaking directory,
Stem Cell dealmaking by technology type, Partnering resource center,
Appendices.
For more information Visit at: http://mrr.cm/J5B
Find all Biotechnology
report at: http://www.marketresearchreports.com/biotechnology
No comments:
Post a Comment
Note: only a member of this blog may post a comment.